Drug data last refreshed 2h ago · AI intelligence enriched 6d ago
INNOVAR is a fixed-dose combination injectable containing droperidol (a butyrophenone antipsychotic) and fentanyl citrate (a potent opioid), used for anesthesia induction and maintenance in surgical settings. This pre-launch NDA product combines neuroleptic and analgesic properties to provide dissociative anesthesia. The combination enables rapid onset and predictable recovery profiles in perioperative environments.
As a pre-launch product, INNOVAR represents a development-stage opportunity with potential for significant team expansion once FDA approval and market entry occur; commercial scale will depend on competitive positioning in the anesthesia induction segment.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
INNOVAR represents a pre-launch career opportunity with AstraZeneca in the perioperative anesthesia space; roles will focus on regulatory approval, market access, and commercial launch readiness. Early-stage involvement offers exposure to product lifecycle management, competitive strategy, and healthcare provider engagement in a specialized segment.
Worked on INNOVAR at AstraZeneca? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.